
    
      This will be a three-site, block randomized (1:1 ratio) double-blind, placebo-controlled
      prospective cross-over study with 50 subjects. Patients will be randomized to receiving
      ziprasidone-washout-placebo or placebo- washout-ziprasidone for 13-weeks.

      Primary and Secondary and safety outcomes: The primary outcome measure will be change from
      baseline Montgomery-Asberg Depression Rating Scale (MADRS) score to end of treatment. Safety
      outcomes will be determined by spontaneously reported adverse events on the case report form.
    
  